Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.

Journal of molecular modeling - 1 Jan 2017

Zhang Jianchun, Ji Tao

Abstract excerpt

Oncogenic BRaf V600E mutation is involved in the development, invasion and metastasis of colon cancer. Selective inhibition of BRafV600E mutant has been recognized as a therapeutic strategy for the cancer. Here, we carried out atomistic molecular dynamics (MD) simulations to characterize the structural basis, energetic property, and dynamics behavior of conformational change in BRaf activation loop upon the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Molecular Dynamics Simulation
Share to Protein Conformation, alpha-Helical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Conformation, beta-Strand

Share to Protein Interaction Domains and Motifs

Share to Static Electricity

Share to Sulfonamides

Share to Thermodynamics

Source

Identifiers

PMID: 27921184
DOI: 10.1007/s00894-016-3177-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.PMID 27921184Read ↗

Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design.Semantic proximity Read ↗

Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.Semantic proximity Read ↗

Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.Semantic proximity Read ↗

An updated literature on BRAF inhibitors (2018-2023).Semantic proximity Read ↗

Combining Molecular Dynamics and Machine Learning to Predict Drug Resistance Causing Variants of BRAF in Colorectal CancerSemantic proximity Read ↗

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022Semantic proximity Read ↗

Bringing Structural Implications and Deep Learning-Based Drug Identification for KRAS Mutants.Semantic proximity Read ↗

Pyrimidin-4-bromobenzenesulfonamide/-4-nitrobenzenesulfonamide hybrids as potential BRAFV600E inhibitors: experimental, computational and biological evaluations.Semantic proximity Read ↗

Mutation-specific structural changes in BRAF: understanding dimerization and drug binding for targeted therapy.Semantic proximity Read ↗

Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors.Semantic proximity Read ↗

In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.Semantic proximity Read ↗

Targeted design, synthesis, molecular simulation, ADME-T and in-vitro anticancer assessment of phenyl-substituted-thioxo-tetrahydro-pyrimidin-benzenesulfonamide derivatives as potential BRAFV600E/WT inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.